This hypothesis is validated by other findings, implying that the HER2-mediated migratory potential of tumor cells could be repressed by anti-CXCR4 antibodies [93]; on the other hand, HER2 suppresses ligand-mediated CXCR4 degradation and thereby potentiates the responding signaling [93]. The gene discussed is ERBB2; the disease is neoplasm.